Differential expression of HLA-DR was used to distinguish macrophages (CD16+DR+) and neutrophils (CD16+DR–) and the expression of galectins Selleck ATM/ATR inhibitor was studied in both subpopulations. A low level of eosinophil counts (< 3%) was observed in samples from both asmathic patients and healthy donors (see Table 2). As shown in Fig. 2a, gal-1 and gal-9 were expressed only on macrophages, while gal-3 expression was detected on both

macrophages and neutrophils. Differential gal expression by macrophages and neutrophils was also confirmed by immunofluorescence staining of sputum cell samples (Fig. 2b). Next, we compared galectin expression between asthma patients and healthy controls. Surface expression of gal-1 and gal-9 was clearly diminished in asthma patients compared with the control group (P < 0·05) (Fig. 3a,b), which is consistent with the Aloxistatin reported action of these proteins as negative regulators of the immune responses [22, 23]. Surface expression of gal-3 was highly variable, and although it tended to be lower in asthmatic patients, this difference did not reach statistical significance (Fig. 3b). Gal-1, gal-9 and especially gal-3 have been linked to allergic conditions. However, we did not find any difference in gal expression between atopic and non-atopic asthma patients, indicating that the lower expression of gal-1 and

gal-9 is independent of atopic status (Fig. 3c). In addition, no significant differences in galectin expression were observed when patients were classified according to the dose of inhaled corticosteroids (Supplementary Table S2). Next, we explored the role of gal-1, gal-3 and gal-9 in the cytokine production induced by LPS. PBMC were stimulated with LPS in the absence or presence of gal-1, gal-3 and gal-9 during 24 h. RT–PCR assays showed that gal-3 reduced the expression of IL-12A induced by LPS (Fig. 4a). When samples were matched it was observed that the reduction of IL-12A

levels occurred in four of five samples tested; however, statistical analysis did Astemizole not show any significant differences (Supplementary Fig. S2a). Gal-9 also caused a mild inhibition of IL-12B in four of five samples included (Fig. 4a and Supplementary Fig. S2b). In addition, we observed a slight increment of TNF-α expression in PBMC stimulated with LPS in the presence of gal-9. However, analysis of matched samples showed that this effect occurs in only three of five samples (Fig. 4a and Supplementary Fig. S2c). Regarding IL-1β, we did not detect any significant difference among treatments (Fig. 4a). Conversely, both gal-1 and gal-9 were able to increase the expression of LPS-induced IL-10 mRNA; in both cases the induction of IL-10 expression was observed in all samples tested (P = 0·01 and P = 0·03, respectively; Fig. 4b and Supplementary Fig. S2d).